Catalyst
Slingshot members are tracking this event:
Ultragenyx (RARE) Presents Second Set of Interim Phase II Data Evaluating KRN23 in Treatment of Tumor-Induced Osteomalacia
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| RARE |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 18, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Interim Data, Phase Ii, Krn23, Tumor-induced Osteomalacia, American Society For Bone Andmineral Research, 2016 Annual Meeting
